A market and risk assessment of 125 turmeric supplements available in Australia, Germany, India, UK, and USA
- PMID: 40773013
- DOI: 10.1007/s00210-025-04392-5
A market and risk assessment of 125 turmeric supplements available in Australia, Germany, India, UK, and USA
Abstract
Historically prominent in Ayurvedic cultures, turmeric (Curcuma longa), or "Haldi," is renowned for its anti-inflammatory and antioxidant effects, mainly due to its active compounds, curcuminoids. Due to the increasing use of turmeric supplements, this study critically examined 125 preparations across the UK, USA, India, Australia, and Germany and evaluated their compliance with evidence-based recommendations. Results reveal significant regulatory and labeling inconsistencies across countries, with 34% of preparations failing to disclose the active curcuminoid content. This lack of dosage regulation is especially concerning when considering the ongoing research into advanced delivery systems-such as nanoparticles, liposomes, micelles, and phospholipid complexes-which significantly enhance curcumin's absorption. Curcumin, a hydrophobic compound, undergoes rapid metabolism in the liver through Phase I and II detoxification pathways, particularly via cytochrome P450 enzymes and UDP-glucuronosyltransferase enzymes. This results in limited bioavailability, as curcumin is rapidly converted to water-soluble metabolites and excreted, reducing its effectiveness at therapeutic doses. However, through modern formulation technologies, curcumin can potentially not only alter drug metabolism, but its antioxidant action via Nrf2 activation can shift to pro-oxidant effects at high doses, causing oxidative stress and the accumulation of reactive metabolites. Emerging evidence suggests chronic low-dose use may lead to gastrointestinal, hepatic, or renal toxicity, yet turmeric preparations, falling within the scope of food law, lack the stringent controls applied to pharmaceuticals and are generally assumed safe. This study highlights the need for transparent labeling, clear dosage guidelines, and an understanding of curcumin's metabolic profile to guide consumers in maximizing benefits while mitigating risks. Furthermore, it aims to assist healthcare professionals in making informed recommendations regarding curcumin supplementation. Further research must include long-term clinical trials and potential standardization of curcumin supplement formulations.
Keywords: Curcuma longa; Bioavailability; Curcuminoids; Detoxification; Drug metabolism; Labeling; Nanoparticles; Oxidative stress; Pro-oxidant; Regulation; Safety; Supplement; Therapeutic doses; Toxicity; Turmeric.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: H.R.-M. declares no conflict of interest. R.S. is the Editor-in-Chief of Naunyn-Schmiedebergs Arch Pharmacol and follows the editorial guidelines of editors acting as editors ( https://link.springer.com/journal/210/submission-guidelines#Instructions%20for%20Authors_Competing%20Interests ). Consent for publication: Not applicable, as publicly available information is used as a data source. Ethics approval: This work was carried out in accordance with the guidelines of good scientific practice of Hannover Medical School ( https://www.mhh.de/en/research/good-scientific-practice ) and officially registered as a doctoral project for Haleema Rahim-Mahdy. Hannover Medical School follows the guidelines of the German Research Foundation (DFG). Consent to participate: This study did not involve human participants directly. The analysis was based solely on publicly available data from freely accessible supplement information sources.
Similar articles
-
Management of urinary stones by experts in stone disease (ESD 2025).Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
-
Turmeric.2025 Jul 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2025 Jul 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000906 Free Books & Documents. Review.
-
Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.Cochrane Database Syst Rev. 2014 Apr 29;2014(4):CD007768. doi: 10.1002/14651858.CD007768.pub3. Cochrane Database Syst Rev. 2014. PMID: 24777444 Free PMC article.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
[Guidelines for the prevention and management of bronchial asthma (2024 edition)].Zhonghua Jie He He Hu Xi Za Zhi. 2025 Mar 12;48(3):208-248. doi: 10.3760/cma.j.cn112147-20241013-00601. Zhonghua Jie He He Hu Xi Za Zhi. 2025. PMID: 40050074 Chinese.
References
-
- 21 CFR §101.17. U.S. Food and Drug Administration (2023) CFR – code of Federal Regulations Title 21. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?f... . Accessed 26 03 2024
-
- 21 CFR §321(ff)(3)(b)(2). U.S. Food and Drug Administration (2023) CFR – code of Federal Regulations Title 21. Accessed on 17.03.2024. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?C...
-
- 21 CFR §101.93. U.S. Food and Drug Administration (2023) CFR – code of Federal Regulations Title 21. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/su... . Accessed on 27 03 2024
-
- 21 CFR §101.36. U.S. Food and Drug Administration (2023) CFR – code of Federal Regulations Title 21. https://www.ecfr.gov/current/title-21/part-101/section-101.36#p-101.36(a) .Accessed 2 04 2024
-
- Abd El-Hack et al (2021) Curcumin, the active substance of turmeric: its effects on health and ways to improve its bioavailability. J Sci Food Agric 101(10):3946–3959. https://doi.org/10.1002/jsfa.11372 - DOI
LinkOut - more resources
Full Text Sources